Global Information
회사소개 | 문의 | 비교리스트

세계의 쇼그렌 증후군 시장(2020-2026년)

Global Sjogren´s Syndrome Acids Market 2020-2026

리서치사 Orion Market Research Pvt Ltd
발행일 2021년 04월 상품코드 1008076
페이지 정보 영문 배송안내 2-3일 (영업일 기준)
가격
US $ 5,125 ₩ 7,280,000 Unprintable PDF (Single User License)
US $ 6,625 ₩ 9,411,000 Unprintable PDF (5 User License)
US $ 8,280 ₩ 11,762,000 Printable PDF (Corporate License)


세계의 쇼그렌 증후군 시장(2020-2026년) Global Sjogren´s Syndrome Acids Market 2020-2026
발행일 : 2021년 04월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 쇼그렌 증후군 시장은 예측기간 중 4.6%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

세계의 쇼그렌 증후군(Sjogren's Syndrome Acids) 시장을 조사했으며, 시장 개요, 시장 성장요인 및 저해요인 분석, 시장 기회, 검사·약제 유형·유형·지역별 시장 규모 추이와 예측, 경쟁 구도, 주요 기업 프로파일 등의 정보를 제공합니다.

목차

제1장 보고서 개요

제2장 시장 개요와 인사이트

  • 조사 범위
  • 애널리스트 인사이트와 현재 시장 동향
  • 규칙

제3장 시장 결정 요인

  • 동기
  • 억제요인
  • 시장 기회

제4장 시장 세분화

  • 약제 유형별
    • Pilocarpine
    • Cyclosporine
    • Hydroxychloroquine
    • Immunosuppressive Agents
  • 유형별
    • 원발성 쇼그렌 증후군
    • 2차 쇼그렌 증후군

제5장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 스페인
    • 프랑스
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 기타 아시아태평양
  • 기타 지역

제6장 기업 개요

  • AbbVie Inc.
  • Amgen Inc.
  • Argentis Pharmaceuticals, LLC
  • AstraZeneca PLC
  • Aldeyra Therapeutics, Inc.
  • Bristol-Myers Squibb Co.
  • Biogen Inc.
  • Demcon Hemics BV.
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Horizon Therapeutics Plc
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • ONO PHARMACEUTICAL CO., LTD
  • Pfizer Inc.
  • Sanofi S.A.
LSH 21.07.16

LIST OF TABLES

  • 1. GLOBAL SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 2. GLOBAL PILOCARPINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL CYCLOSPORINE MARKET RESEARCH AND ANALYSIS BY TEST, 2020-2027 ($ MILLION)
  • 4. GLOBAL IMMUNOSUPPRESSIVE AGENTS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL HYDROXYCHLOROQUINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY TYPE 2020-2027 ($ MILLION)
  • 7. GLOBAL PRIMARY SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL SECONDARY SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL SJOGREN'S SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. NORTH AMERICAN SJOGREN'S SYNDROMEMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 11. NORTH AMERICAN SJOGREN'S SYNDROMEMARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 12. EUROPEAN SJOGREN'S SYNDROMEMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 13. EUROPEAN SJOGREN'S SYNDROMEMARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 14. ASIA-PACIFIC SJOGREN'S SYNDROMEMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 15. ASIA-PACIFIC SJOGREN'S SYNDROMEMARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)
  • 16. REST OF THE WORLD SJOGREN'S SYNDROMEMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 17. REST OF THE WORLD SJOGREN'S SYNDROMEMARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL SJOGREN'S SYNDROME MARKET SHARE BY TEST, 2020 VS 2027 (%)
  • 2. GLOBAL BLOOD TEST FOR SJOGREN'S SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 3. GLOBAL EYE TEST FOR SJOGREN'S SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 4. GLOBAL IMAGING TEST FOR SJOGREN'S SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 5. GLOBAL BIOPSY FOR SJOGREN'S SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 6. GLOBAL SJOGREN'S SYNDROMEMARKET SHARE BY DRUG TYPE, 2020 VS 2027 (%)
  • 7. GLOBAL PILOCARPINE FOR SJOGREN'S SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 8. GLOBAL CYCLOSPORINE FOR SJOGREN'S SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL HYDROXYCHLOROQUINE FOR SJOGREN'S SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 10. GLOBAL IMMUNOSUPPRESSIVE AGENTS FOR SJOGREN'S SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 11. GLOBAL SJOGREN'S SYNDROMEMARKET SHARE BY TYPE, 2020 VS 2027 (%)
  • 12. GLOBAL PRIMARY SJOGREN SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 13. GLOBAL SECONDARY SJOGREN SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 14. GLOBAL SJOGREN'S SYNDROME MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 15. GLOBAL PLATFORM SJOGREN'S SYNDROMEMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 16. US SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 17. CANADA SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 18. UK SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 19. FRANCE SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 20. GERMANY SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 21. ITALY SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 22. SPAIN SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 23. REST OF EUROPE SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 24. INDIA SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 25. CHINA SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 26. JAPAN SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 27. SOUTH KOREA SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 28. REST OF ASIA-PACIFIC SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)
  • 29. REST OF THE WORLD SJOGREN'S SYNDROMEMARKET SIZE, 2020-2027($ MILLION)

Global Sjogren's Syndrome Acids Market Size, Share & Trends Analysis Report by Test (blood test, Eye test, imaging test, and Biopsy), By Drug Type (Pilocarpine, Cyclosporine, Hydroxychloroquine, and Immunosuppressive Agents), Type (Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome) and Forecast 2021-2027

Global Sjogren's Syndrome market is anticipated to grow at a CAGR of 4.6% during the forecast period. Sjogren's syndrome is a disorder of the human immune system whereby it affects the parts of the body that produces fluids such as saliva, tears. It's a long- term condition that affects one's daily life and is more common in women than men that usually starts at age 40 to 60. Sjogren also affects the other parts of the body such as kidneys, joints, lungs, nerves, blood vessels. The treatment focuses on relieving the symptoms such as fiving artificial tears for dry eyes, sucking sugar free candies and drinking gallons of water for dry mouth along with taking some medicines. The factors contributing to the market growth include a growing population with several diseases that can cause Sjogren's syndrome and increasing demand for advanced treatment for Sjogren's syndrome. Other factors include increased use of contact lens that leads to dryness of eyes, unhealthy lifestyle adoption, increased advanced treatment of eye diseases and growing diseases like rheumatoid arthritis and lupus are propelling the growth of the market.

However, a lack of awareness among the population about Sjogren's syndrome restrains the growth of the market. Further lack of proper cure treatments is also projected to hamper the growth of the market. Currently, available treatment options are either ineffective in patients with the following syndrome or only relieve the symptoms. Increasing lab automation rates and technological advances will bring upon opportunities for the growth of the market. Additionally, rising government initiatives such as the North American Rheumatoid Arthritis consortium are educating healthcare professionals and patients regarding the diagnosis and its treatment will boost the growth of the Sjogren's syndrome market.

Segmental Outlook

The global Sjogren's syndrome market is segmented based on the test, drug type and type. based on test market are segmented blood test, Eye test, imaging test and biopsy. Based on a Drug type, the market is segmented into pilocarpine, cyclosporine, hydroxychloroquine, and immunosuppressive agents. On the basis of type, the market is segmented into primary Sjogren's syndrome and secondary Sjogren's syndrome.

Global Sjogren's Syndrome Market Share by Type, 2020(%)

Source: OMR Global

Secondary Sjogren's Syndrome Segment is Anticipated to Dominate the Global Sjogren's Syndrome Market

Secondary Sjogren's Syndrome is projected to hold a significant share in the global Sjogren's Syndrome market. The factors contributing to the market growth include the growing prevalence of autoimmune diseases such as rheumatoid arthritis. One of the most common causes of secondary Sjogren's syndrome include rheumatoid arthritis. This kind of diagnosis has the following conditions including primary biliary cholangitis, lupus, scleroderma and others. In secondary Sjogren's syndrome, the doctor will be going through complete medical history and conduct a physical exam. The diagnosis will be including blood work that usually looks for proteins and markers specific to Sjogren's. It also includes a lower lip biopsy to look for clusters of inflammatory cells.

Regional Outlook

The global Sjogren's Syndrome Market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America and Europe have a significant contribution to the global Sjogren's Syndrome acid market. The growth of the market mainly driven due to the increasing number of autoimmune diseases such as rheumatoid arthritis, lupus, growing demand for advanced treatments solutions for such diseases and increasing prevailing rates of Sjogren's syndrome in the region.

Source: OMR Global

Asia-Pacific will Have Considerable Growth in the Global Sjogren's Syndrome Market

Asia Pacific region is forecasted to exhibit rapid growth of Sjogren's syndrome market due to rising healthcare infrastructure in the region, the rise of diagnosis of Sjogren's disease, and increasing government expenditure in the healthcare sector are driving the growth of the Sjogren's syndrome market in the region. According to Sage publications 2019, almost 68.59% of Chinese patients had dry eye prevalence, and 86.5% had dry mouth prevalence in Chinese patients additionally 6.9% of Chinese patients had arthritis. Further, the increasing prevalence of Sjogren's syndrome and the rise of such diagnosis also drive the growth of the market. However, lack of proper treatment options, lack of awareness and affordability are the factors restraining the growth of the market in underdeveloped countries such as the Middle East and Africa.

Market Players Outlook

The key players of the Sjogren's Syndrome market include AbbVie Inc., Amgen Inc., Argentis Pharmaceuticals, LLC, AstraZeneca PLC, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers, and acquisitions, collaborations, and new product launch, to stay competitive in the market. For instance, in July 2020, UniQuest partnered with CSL Ltd for developing and commercializing its antigen immune tolerance induction technology for treating Sjogren's syndrome. The main purpose of this collaboration was to identify liposome-encapsulated antigen candidates for Sjogren's syndrome and then shepherd the lead candidate towards its clinical trials. This technology has the potential to treat patients suffering from autoimmune diseases.

The Report Covers

  • Market value data analysis of 2020 and forecast to 2027.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global Sjogren's Syndrome Acids
  • market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Regulations

3. Market Determinants

  • 3.1. Motivators
  • 3.2. Restraints
  • 3.3. Opportunities

4. Market Segmentation

  • 4.1. Global Sjogren's Syndrome Market by Drug Type
    • 4.1.1. Pilocarpine
    • 4.1.2. Cyclosporine
    • 4.1.3. Hydroxychloroquine
    • 4.1.4. Immunosuppressive Agents
  • 4.2. Global Sjogren's Syndrome Market by Type
    • 4.2.1. Primary Sjogren's Syndrome
    • 4.2.2. Secondary Sjogren's Syndrome

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AbbVie Inc.
  • 6.2. Amgen Inc.
  • 6.3. Argentis Pharmaceuticals, LLC
  • 6.4. AstraZeneca PLC
  • 6.5. Aldeyra Therapeutics, Inc.
  • 6.6. Bristol-Myers Squibb Co.
  • 6.7. Biogen Inc.
  • 6.8. Demcon Hemics BV.
  • 6.9. Daiichi Sankyo Co., Ltd.
  • 6.10. Eisai Co., Ltd.
  • 6.11. F. Hoffmann-La Roche Ltd.
  • 6.12. Horizon Therapeutics Plc
  • 6.13. Novartis AG
  • 6.14. Otsuka Pharmaceutical Co., Ltd.
  • 6.15. ONO PHARMACEUTICAL CO., LTD
  • 6.16. Pfizer Inc.
  • 6.17. Sanofi S.A.
Back to Top
전화 문의
F A Q